Tag Archives: Actavis

Teva stock crashes on 2Q earnings disaster; run for the hills, or buy at fire sale price?

The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »



Allergan wraps up 2016 M&A with LifeCell buy for $2.9 billion; analysts lavish kudos all around

Dublin-based Allergan said on December 19, 2016 it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP (San Antonio TX), for $2.9 billion in cash, bringing… Read more »



Feds charge Heritage execs with price fixing; DOJ ringing out 2016 on a roll against Pharma offenses

The former chief executive and former president of generic drug company Heritage Pharmaceuticals Inc. (Eatontown, NJ) have been charged with conspiring to fix prices, the first charges in a continuing… Read more »



New Inversion Rules Test Pending Deals, WSJ Reports

The U.S. Treasury Department’s latest attempt at stopping corporate inversions last week spelled doom for Pfizer Inc.’s (New York City) $150 billion attempted takeover of Allergan PLC (Dublin IRL)–what would… Read more »